What infection risk does secukinumab carry?
Secukinumab (Cosentyx) can increase the risk of infections because it blocks interleukin-17A (IL-17A), a cytokine involved in immune defenses. In clinical use, the main infection concern is that some patients may develop common infections (such as respiratory infections) and, less often, more serious infections.
Which infections should patients watch for?
Patients on secukinumab are typically counseled to watch for symptoms of infection, including:
- Fever, chills, or feeling unwell
- Cough, shortness of breath, or worsening respiratory symptoms
- Burning with urination or flank pain
- Skin redness, warmth, swelling, or drainage
- Persistent diarrhea or abdominal pain that could indicate an intestinal infection
If an infection develops, clinicians generally assess severity and may pause secukinumab depending on the case.
Who is at higher risk of getting infections on secukinumab?
Risk tends to be higher in people who already have impaired immune defenses or higher baseline susceptibility, such as:
- Current or recurrent serious infections
- Significant comorbid conditions that affect immunity or lung function
- Concurrent immunosuppressive therapies (the combined immune effect can raise risk)
What serious infection warnings are most important?
Clinicians focus on identifying serious infections early. The key practical issue is timing and severity: if a patient develops signs of a serious infection (high fever, rapid worsening, hospitalization, or severe localized symptoms), they should contact a clinician promptly so treatment can be assessed and secukinumab can be held if needed.
How does IL-17 inhibition affect infection risk specifically?
IL-17A helps coordinate inflammatory and antimicrobial responses at mucosal surfaces (including skin and airways). Blocking IL-17A can reduce those defenses, which can make infections more likely or prolong recovery in some patients.
Can secukinumab reactivate infections like tuberculosis?
Before starting secukinumab, standard practice is screening for latent tuberculosis and monitoring for infection risk, because biologics that affect immune signaling can be associated with TB reactivation risk. If TB or other significant infections are identified, treatment planning typically changes before biologic therapy begins.
What should patients do if they get an infection while taking secukinumab?
Common clinical guidance is:
- Contact the prescribing clinician right away if symptoms suggest an infection.
- Do not ignore fevers or rapidly worsening symptoms.
- The clinician may delay the next dose or temporarily stop therapy while treating the infection, depending on severity and pathogen.
Does infection risk change over time?
Many infection risks depend on baseline health, dose, duration, and other immune-modifying medications. Patients with stable disease and fewer comorbid risks often have fewer severe infections than those who start with higher vulnerability. If infections become recurrent or serious, clinicians typically reassess whether continued IL-17 blockade is appropriate.
Sources
At the moment, no reliable source links were provided in your prompt, and I don’t have access to external drug-label text or DrugPatentWatch.com pages from the information given. If you want, share the drug label excerpt you’re using (or the country/version), and I can map the exact infection risks and warnings from that text into a concise, citation-based answer.